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Abstract
Background: The X-linked recessive primary immunodeficiency disease (PIDD) Wiskott-Aldrich syndrome (WAS) is
identified by an extreme susceptibility to infections, eczema and thrombocytopenia with microplatelets. The
syndrome, the result of mutations in the WAS gene which encodes the Wiskott-Aldrich protein (WASp), has wide
clinical phenotype variation, ranging from classical WAS to X-linked thrombocytopaenia and X-linked neutropaenia.
In many cases, the diagnosis of WAS in first affected males is delayed, because patients may not present with the
classic signs and symptoms, which may intersect with other thrombocytopenia causes.
Case presentation: Here, we describe a three-year-old HIV negative boy presenting with recurrent infections, skin
rashes, features of autoimmunity and atopy. However, platelets were initially reported as normal in numbers and
morphology as were baseline immune investigations. An older male sibling had died in infancy from suspected
immunodeficiency. Uncertainty of diagnosis and suspected severe PIDD prompted urgent further molecular
investigation. Whole exome sequencing identified c. 397 G > A as a novel hemizygous missense mutation located in
exon 4 of WAS.
Conclusion: With definitive molecular diagnosis, we could target treatment and offer genetic counselling and
prenatal diagnostic testing to the family. The identification of novel variants is important to confirm phenotype
variations of a syndrome.
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Background
Wiskott-Aldrich syndrome (WAS) occurs due to muta-
tions in the WAS gene, located at Xp11.22-p11p23 [1, 2].
It is a rare X-linked recessive primary immunodeficiency
disease (PIDD) originally described by the features of ex-
cess susceptibility to infections, eczema and micro-
thrombocytopenia leading to bleeding disorders such as
bloody diarrhea [1, 3, 4]. This is considered the most se-
vere type, which often results in the development of
autoimmunity, lymphoma or other malignancies. WAS
almost exclusively affects males and the estimated inci-
dence is less than 1 in 100,000 live births [5]. One of the
hallmark characteristics of this disease is microthrombo-
cytopenia, which is observed on a blood film and subse-
quently quantified using blood analysers [6]. In many
cases, the diagnosis of WAS in first affected males is de-
layed because patients may not present with the classic
signs and symptoms, which may intersect with
thrombocytopenia causes [7–9]. In addition to classic
WAS (50%) with total loss of function mutation, WAS
mutations in are also associated with other disorders.
Reduced WAS protein function mutations results inX-
linked thrombocytopenia (XLT) (50%), while gain of
function mutations cause the ultra-rare X-linked neutro-
penia (XLN) [7–9].
The WAS gene encodes the Wiskott-Aldrich syndrome
protein (WASp), which consists of 502 amino acids and
is a key regulator of actin cytoskeletal rearrangements
[1]. Hematopoietic cells exclusively express WASp and
the protein is implicated in a variety of functions such as
immune synapse formation and cellular migration and
hence impaired T and B cell function [10, 11]. Small
platelets and congenital thrombocytopenia with a mean
platelet volume of less than 5.0 fL in most affected per-
sons are considered key to the diagnosis of WAS [10,
12]. We present the findings of an infant male patient
with atypical features of WAS, suspected because of the
clinical course and a relevant family history, although his
platelets were initially normal in size and morphology.
The demonstration of a novel mutation in WAS by ex-
ome sequencing provided a definitive diagnosis for ap-
propriate treatment recommendations and counselling.
Case presentation
At 16-weeks the infant was transferred to our hospital
with pneumonia requiring assisted ventilation after pro-
longed hospitalization at a peripheral hospital. There he
had presented with pneumonia and acute severe malnu-
trition, history of intermittent diarrhea, fevers and ecze-
matoid skin rashes since 6 weeks of age. During the
months of hospitalization, he developed Group B
streptococcal bacteremia and pneumonia, cytomegalo-
virus (CMV) pneumonia and persistent viraemia, septic
purulent knee, furuncles, buttock abscess, haemolytic
anaemia, features of inflammatory bowel disease respon-
sive to immune suppression, eosinophilic gastritis and
multiple food allergies.
He developed chronic CMV viraemia requiring pro-
longed ganciclovir administration. The infant remained
severely malnourished but never had signs of oedema.
Ongoing diffuse erythrodermatous rashes appeared vas-
culitic (confirmed leukocytoclastic on histology) in areas,
while other areas were more suggestive of eczema. The
birth and perinatal history had been uncomplicated; the
infant was exclusively breastfed and had tolerated pri-
mary vaccinations well including live BCG. A timeline
for the presentation of symptoms of the index case is
shown in Supplementary Fig. 1.
There is no evidence for consanguinity of the parents.
The family history was relevant however, for a 21-month
older male sibling who had died at 8 months of age from
infections. Perinatal history was normal, and the infant
was breastfed. He had severe eczema since birth, failure
to thrive and repeatedly documented low platelet counts.
He had presented at 4 months to another hospital and
was diagnosed with pneumocystis pneumonia and CMV
infection. Platelet morphology and size were not re-
corded, but dysmorphic platelets with normal produc-
tion of platelets were reported on a bone marrow
aspirate done at the time of sepsis. Baseline immune in-
vestigations were normal. He demised with an undefined
immunodeficiency diagnosis after unsuccessful evalu-
ation for stem cell transplant (Fig. 1).
On systemic examination of the index patient at 16
weeks of age, there were no signs of dysmorphism, no
enlarged lymph nodes nor hepatosplenomegaly. Human
immuno- deficiency virus (HIV) polymerase chain reac-
tion (PCR) of the infant and the mother’s HIV enzyme-
linked immunosorbent assay (ELIZA) were negative. Ini-
tial full blood count (FBC) indicated normal white cell
Fig. 1 Multigeneration pedigree of the Wiskott Aldrich
Syndrome family
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count and lymphocyte count, normocytic anaemia, eo-
sinophilia and mild thrombocytopenia with a normal
smear and no anomaly noted in platelet morphology.
Platelet counts recovered on ganciclovir therapy for
CMV infection. Investigations for immune deficit in-
cluded serum immunoglobulins, expanded T cell subsets
and T cell receptor excision circle (TREC) screening
which were all normal, however elevated serum IgE
levels were recorded. A summary of the all blood results
is shown in Table 1. Following the WAS molecular diag-
nosis, electron microscopic exam of platelets confirmed
microplatelets with reduced platelet diameter compared
to adult controls. Gradually worsening thrombocyto-
paenia evolved over the first year of life but he did not
suffer from any bleeding episodes. He was initially
treated for undefined severe immunodeficiency and eval-
uated for stem cell transplantation, which the parents re-
fused despite intensive counseling.
The Health Research Ethics Committee of Stellen-
bosch University approved this study (study no. N13/05/
075) and the ethical guidelines described in the “Declar-
ation of Helsinki, 2013” were observed [13] . The parents
of the affected infant child provided written informed
consent which included permission for the genetic
evaluation of the patient.. Venous blood for DNA extrac-
tion (using the Nucleon BACC3 Kit (Amersham Biosci-
ences, Buckinghamshire, UK)) and whole exome
sequencing (WES) was drawn from the affected child (1
ml) and both of his parents (5 ml).. An additional 5 ml of
blood was drawn from the patient for full blood counts,
platelet counts as well as electron microscopy.
Exome capture and sequencing
The Ion AmpliSeq™ Exome RDY Kit as well as the Ion
Xpress™ Barcode Adaptors 1–16 Kit (Life Technologies,
Carlsbad, California, United States) were used for library
preparation. Following this, the Ion PI™ Hi-Q™ Chef Kit
followed by the Ion PI™ Chip Kit v3 was used to prepare
the template DNA on the Ion Chef system. Sequencing
reactions were conducted using the Ion Proton™
(Thermo Fisher, Carlsbad, California, United States) at
Stellenbosch University’s Central Analytical Facility
(CAF).
Mapping, variant detection and annotation of variants
The Torrent Mapping Alignment Program (TMAP ver-
sion 5.2.1) was used to align sequences to the human
reference genome hg19 using the ion-analysis workflow
available as part of the Torrent Suite (version 5.2.1). The
variant caller (version 5.2.1.1) plugin on the Torrent
suite was used for initial variant discovery and to subse-
quently generate a variant call format (VCF) file. Variant
annotation was done using ANNOVAR [14]. To
prioritize variants, a custom-designed, in-house method
called TAPER™ was used [15].
Sanger sequencing
A fragment of 275 base pairs containing the variant of
interest was amplified by polymerase chain reaction
from genomic DNA obtained from the patient and his
parents. The following primers were designed: WASF-
5′ GTGGAGAGGAGATGGGAAAG − 3′ and WASR-
5′ CTGTGGATAGATGGATTGGGA-3′. Each ampli-
con was sequenced in a forward and reverse direction at
Stellenbosch University’s Central Analytical Facility in
Cape Town South Africa.
Transmission Electron microscopy
Blood was centrifuged at 3000 rpm for 5 min. Plasma
was subsequently removed and 2.5% Glutaraldehyde in
0.1M buffer was added as the fixative. This was left to
fix for 18 h. Platelets were removed, and 3% Osmium
was added and left at room temperature for 1 h. The
fixed sample was subsequently processed on a Leica
Electron Microscopic Tissue Processor (Wetzlar,
Germany). The following resins were added: 2% Uranyl
acetate for 30 min, then 2X 70% alcohol 5 min each. 96%
alcohol 5 min, 2% Uranyl nitrate 10 min, 100% alcohol
for 10 min, 100% alcohol for 15 min; 100% alcohol for
20 min, 50/50 mixture of 100% alcohol and resin for 90
min, then both resins for 1 h each. The processed sample
was then embossed in capsules filled with resin and
placed in an incubator overnight at 65 °C. The sample
was cut and stained with Toluidine Blue O for
visualisation.
Genetics findings
Uncertainty of diagnosis and suspected severe PIDD
prompted urgent molecular investigation for our patient.
Initial diagnoses included combined immunodeficiency
or leaky severe combined immunodeficiency (SCID) and
a bone marrow transplant was discussed but refused by
the parents. The results obtained from the exome se-
quencing for the patient as well as his parents are pre-
sented in Supplementary Table 1. Data were filtered to
prioritize rare and novel variants and a shortlist of three
candidate variants was obtained (Supplementary Table
2). A novel hemizygous variant, c. 397 G > A in exon 4
of WAS (NM_000377.3), was identified in the patient.
This results in the substitution of glutamic acid to lysine
at position 133 (E133K). Furthermore, applying the
American College of Medical Genetics standards and
guidelines to interpret sequence variants [16], this vari-
ant has been classed as likely pathogenic (One moderate
and three supporting; PM2, PP2, PP3 and PP4).
The presence of the variant was validated by Sanger
sequencing and the mutation details are summarized in








































































































































































































































































































































































































































































Glanzmann et al. BMC Medical Genetics          (2020) 21:124 Page 4 of 8
Supplementary Table 3. It was determined that the
mother is a heterozygous carrier of the variant, while it
is completely absent in the father (Fig. 2). SIFT and
PolyPhen2 was used for in silico predictions and indi-
cated that WAS c. 397 G > A mutation found that it is
damaging (Supplementary Table 3). Sequence alignment
of multiple different species show that WAS c. 397 G > A
is located at a position that is relatively well conserved
across multiple species (Fig. 3). Further analysis of the
protein identified that the variant is found in a WH1 do-
main, which is in control of the binding of proline-rich
sequences in WASp. Moreover, analysis of the protein
revealed that the amino acid substitution is from an
amino acid with a negative charged to one which is posi-
tively charged and is therefore likely to affect protein
folding.
Microscopy findings
Following the identification of the E133K variant in
WAS, platelet size and morphology were re-evaluated
using transmission electron microscopy. This subse-
quent re-evaluation showed that the platelets of the pa-
tient are significantly smaller than those of a healthy
aged-matched control individual (p = 5,627e− 14) (Fig. 4).
Fig. 2 Sanger sequencing of proband (indicated by black arrow) and each of his unaffected parents. The mother of the proband is heterozygous
for the WAS c.397G > A (p.133 E > K) while the proband is hemizygous for the mutation
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Discussion and conclusion
To date, there are a total of three WAS protein mutation
associated syndromes. These include classic WAS, con-
genital neutropenia without other WAS features and X-
linked thrombocytopenia features [17, 18]. Here we
summarise the case of a patient who presented with
what was initially thought to be a combined or variant
severe immunodeficiency. The diagnosis of WAS was
considered in our patient because of his family history,
despite initial normal platelet count and difficulty in es-
tablishing platelet volume and size measurements on
routine analysis. Very few case descriptions of WAS pa-
tients with normal platelet size have been reported. In a
study conducted by Patel et al. a young boy was the
index case and presented with normal platelet size and
thrombocytopenia. Given the clinical phenotype, WASp
expression was evaluated using flow cytometry [19]. The
index case had decreased expression of the protein when
compared to a healthy individual. A c.826 A > T
(K288X) mutation in exon 9 of the WAS gene was iden-
tified. WASp flow cytometric analysis was unfortunately
not available for our patient. Using exome sequencing,
we could identify a novel c.397 G > A (E133K) WAS mu-
tation in exon 4.
The variant reported here was not found in any add-
itional controls that were subjected to exome sequencing
and it was determined that the variant falls in the WH1
domain. This domain is important as it binds to proline-
rich sequences in the WASp interacting protein. Fur-
thermore, it is anticipated that this domain has a vital
role in numerous cellular events including signal trans-
duction, protein folding and transport [18]. The identifi-
cation of a novel variant in our patient in a hemizygous
form, of which his mother is a carrier, will permit family
counselling in the case of future pregnancies. Moreover,
an early and accurate prenatal diagnosis by molecular
testing such as exome sequencing will prevent poten-
tially harmful procedures for example live vaccine ad-
ministration and intramuscular injections, thereby
preventing severe infection and internal bleeding. The
patient currently receives home administered subcutane-
ous immunoglobulin and prophylactic antibiotics, eats a
modified diet and continues in reasonable health, but is
still failing to thrive.
Despite a positive family history of suspected PIDD in
a deceased sibling, the definitive diagnosis in this child
was complex. This was firstly due to repeated haematol-
ogy laboratory reports of platelet clumping with use of
Fig. 4 Mean platelet size of the patient versus the healthy control. The platelet size of the patient is significantly smaller than that of the healthy
control, with a P-value of 5627e− 14
Fig. 3 ClustalW multiple sequence alignment showing the position of the c.397G > A (p.133 E > K) mutation in WAS
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conventional EDTA anticoagulation tubes. This led to
suspicion of pseudothrombocytopenia due to antibody-
induced platelet clumping or satellitism. Only once
blood sampling in Sodium citrate anticoagulated tubes
was applied routinely, were reliable reports of moderate
thrombocytopaenia and reduced mean platelet volume
obtained on automated analyzers from 1 year of age.
Secondly the thrombocytopaenia reported with platelet
clumping was further difficult to interpret against the
clinical background with CMV infection and viral resist-
ance. In addition to these complications, scanning elec-
tron microscopy is not routinely available to patients in
South Africa, however it proved useful in this case be-
cause repeated platelet clumping on EDTA sampled
blood. Eventual citrate anticoagulated blood samples by
EM showed reduced MPV, whereas on automated pro-
cessing this was only observed inconsistently. Further-
more micro thrombocytopaenia is not a reliable marker
of WAS. In this setting, access to molecular diagnosis in
a developing country, enabled us to make a confirmed
PIDD diagnosis and counsel the mother who was in de-
nial to accept such diagnosis.
The early diagnosis of WAS will also enable prompt
referral for stem cell transplantation in severely affected
patients. WAS is an extremely rare disorder with a broad
clinical spectrum. Our data supports that of Baharin
et al. [5] which suggests that a WAS diagnosis must be
deliberated on for all male infants presenting with con-
genital thrombocytopenia irrespective of platelet size,
with excess of infections and skin rashes and specifically
in those where there is a recorded family history of un-
explained male infant deaths.
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